Hytrin (BioDeep_00000015110)

   


代谢物信息卡片


Terazosin hydrochloride dihydrate

化学式: C19H30ClN5O6 (459.18845100000004)
中文名称: 盐酸特拉唑嗪 二水合物
谱图信息: 最多检出来源 () 0%

分子结构信息

SMILES: COC1=C(C=C2C(=C1)C(=NC(=N2)N3CCN(CC3)C(=O)C4CCCO4)N)OC.O.O.Cl
InChI: 1H

描述信息

C78272 - Agent Affecting Nervous System > C29747 - Adrenergic Agent > C72900 - Adrenergic Antagonist
D018377 - Neurotransmitter Agents > D018663 - Adrenergic Agents > D018674 - Adrenergic Antagonists
D000089162 - Genitourinary Agents > D064804 - Urological Agents
Terazosin hydrochloride dihydrate is a quinazoline derivative and a competitive and orally active α1-adrenoceptor antagonist. Terazosin hydrochloride dihydrate works by relaxing blood vessels and the opening of the bladder. Terazosin hydrochloride dihydrate has the potential for benign prostatic hyperplasia (BPH) and high blood pressure treatment[1][2][3].

同义名列表

3 个代谢物同义名

Terazosin hydrochloride dihydrate; Hytrin; Terazosin (hydrochloride dihydrate)



数据库引用编号

6 个数据库交叉引用编号

分类词条

相关代谢途径

Reactome(0)

BioCyc(0)

PlantCyc(0)

代谢反应

0 个相关的代谢反应过程信息。

Reactome(0)

BioCyc(0)

WikiPathways(0)

Plant Reactome(0)

INOH(0)

PlantCyc(0)

COVID-19 Disease Map(0)

PathBank(0)

PharmGKB(0)

0 个相关的物种来源信息

在这里通过桑基图来展示出与当前的这个代谢物在我们的BioDeep知识库中具有相关联信息的其他代谢物。在这里进行关联的信息来源主要有:

  • PubMed: 来源于PubMed文献库中的文献信息,我们通过自然语言数据挖掘得到的在同一篇文献中被同时提及的相关代谢物列表,这个列表按照代谢物同时出现的文献数量降序排序,取前10个代谢物作为相关研究中关联性很高的代谢物集合展示在桑基图中。
  • NCBI Taxonomy: 通过文献数据挖掘,得到的代谢物物种来源信息关联。这个关联信息同样按照出现的次数降序排序,取前10个代谢物作为高关联度的代谢物集合展示在桑吉图上。
  • Chemical Taxonomy: 在物质分类上处于同一个分类集合中的其他代谢物
  • Chemical Reaction: 在化学反应过程中,存在为当前代谢物相关联的生化反应过程中的反应底物或者反应产物的关联代谢物信息。

点击图上的相关代谢物的名称,可以跳转到相关代谢物的信息页面。



文献列表

  • Lian-Lian Fan, Mu-Peng Li, Tong Wu, Chun-Yan Gan, Pei-Wen Zhang, Gang Mai, Jian-Zhong Shen-Tu. Bioequivalence study of two formulations of terazosin hydrochloride capsule in healthy Chinese subjects under fasting and fed conditions. International journal of clinical pharmacology and therapeutics. 2022 Jan; 60(1):57-66. doi: 10.5414/cp204018. [PMID: 34672254]
  • Sreenivasulu Kilari, Amit Sharma, Chenglei Zhao, Avishek Singh, Chuanqi Cai, Michael Simeon, Andre J van Wijnen, Sanjay Misra. Identification of novel therapeutic targets for contrast induced acute kidney injury (CI-AKI): alpha blockers as a therapeutic strategy for CI-AKI. Translational research : the journal of laboratory and clinical medicine. 2021 09; 235(?):32-47. doi: 10.1016/j.trsl.2021.03.005. [PMID: 33711514]
  • Alireza Farshi, Nooriyeh DalirAkbari, Afshar Zomorrodi, Mohammad Khalili, Mahsa Mahmoudinezhad. A Randomized Crossover Pilot Study Examining the Effect of Carvedilol and Terazosin plus Enalapril on Urinary Symptoms of Patients with Hypertension and Benign Prostatic Hyperplasia. Urology journal. 2021 Apr; 18(3):337-342. doi: 10.22037/uj.v18i.5678. [PMID: 33840085]
  • Gregory L Hundemer, Greg A Knoll, William Petrcich, Swapnil Hiremath, Marcel Ruzicka, Kevin D Burns, Cedric Edwards, Ann Bugeja, Emily Rhodes, Manish M Sood. Kidney, Cardiac, and Safety Outcomes Associated With α-Blockers in Patients With CKD: A Population-Based Cohort Study. American journal of kidney diseases : the official journal of the National Kidney Foundation. 2021 02; 77(2):178-189.e1. doi: 10.1053/j.ajkd.2020.07.018. [PMID: 32920153]
  • Gabriel Onn Kit Loh, Emily Yii Ling Wong, Yvonne Tze Fung Tan, Loke Meng Ong, Ru Shing Ng, Hong Chin Wee, Kok Khiang Peh. Simple and fast LC-MS/MS method for quantification of terazosin in human plasma and application to bioequivalence study. Journal of chromatography. B, Analytical technologies in the biomedical and life sciences. 2021 Jan; 1163(?):122517. doi: 10.1016/j.jchromb.2020.122517. [PMID: 33429127]
  • Makinna C Oestreich, Robin Wm Vernooij, Niranjan J Sathianathen, Eu Chang Hwang, Gretchen M Kuntz, Alex Koziarz, Charles D Scales, Philipp Dahm. Alpha-blockers after shock wave lithotripsy for renal or ureteral stones in adults. The Cochrane database of systematic reviews. 2020 11; 11(?):CD013393. doi: 10.1002/14651858.cd013393.pub2. [PMID: 33179245]
  • Yaser Pashaei, Bahram Daraei, Maryam Shekarchi. Magnetic-Dispersive Solid Phase Extraction Based on Graphene Oxide-Fe3O4 Nanocomposites Followed by High Performance Liquid Chromatography-Fluorescence for the Preconcentration and Determination of Terazosin Hydrochloride in Human Plasma. Journal of chromatographic science. 2020 Jan; 58(2):178-186. doi: 10.1093/chromsci/bmz085. [PMID: 31746326]
  • Mahmoud Roushani, Zeynab Jalilian, Azizollah Nezhadali. A novel electrochemical sensor based on electrode modified with gold nanoparticles and molecularly imprinted polymer for rapid determination of trazosin. Colloids and surfaces. B, Biointerfaces. 2018 Dec; 172(?):594-600. doi: 10.1016/j.colsurfb.2018.09.015. [PMID: 30218985]
  • Mahmoud A Omar, Mohamed A Hammad, Baher I Salman. Micellar enhanced spectrofluorimetric approach for nanogram detection of certain α1 -blocker drugs: Application in pharmaceutical preparations and human plasma. Luminescence : the journal of biological and chemical luminescence. 2018 Nov; 33(7):1226-1234. doi: 10.1002/bio.3539. [PMID: 30094938]
  • Mahmoud A Omar, Abdel-Maaboud I Mohamed, Sayed M Derayea, Mohamed A Hammad, Abobakr A Mohamed. An efficient spectrofluorimetric method adopts doxazosin, terazosin and alfuzosin coupling with orthophthalaldehyde: Application in human plasma. Spectrochimica acta. Part A, Molecular and biomolecular spectroscopy. 2018 Apr; 195(?):215-222. doi: 10.1016/j.saa.2018.01.077. [PMID: 29414581]
  • Jun-Jun Huang, Zhi-Han Zhang, Fei He, Xia-Wen Liu, Xing-Jie Xu, Li-Jun Dai, Qi-Meng Liu, Mu Yuan. Novel naftopidil derivatives containing methyl phenylacetate and their blocking effects on α1D/1A-adrenoreceptor subtypes. Bioorganic & medicinal chemistry letters. 2018 02; 28(4):547-551. doi: 10.1016/j.bmcl.2018.01.068. [PMID: 29422390]
  • Zhe-Xian Deng, Ling-Xiao Ji, Yi-Rong Zhang, Cheng-di Li, Jian Cai, Hai-Hong Jiang. [Ningmitai Capsules relieve lower urinary tract symptoms in patients with benign prostatic hyperplasia : A short-term clinical observation]. Zhonghua nan ke xue = National journal of andrology. 2018 Jan; 24(1):72-77. doi: . [PMID: 30157365]
  • Tong-Xin Yang, Bang-Hua Liao, Yun-Tian Chen, Hong Li, Qing He, Qin-Yu Liu, Kun-Jie Wang. A network meta-analysis on the beneficial effect of medical expulsive therapy after extracorporeal shock wave lithotripsy. Scientific reports. 2017 10; 7(1):14429. doi: 10.1038/s41598-017-14862-3. [PMID: 29089544]
  • Mohamed A Hammad, Mahmoud A Omar, Baher I Salman. Utility of Hantzsch reaction for development of highly sensitive spectrofluorimetric method for determination of alfuzosin and terazosin in bulk, dosage forms and human plasma. Luminescence : the journal of biological and chemical luminescence. 2017 Sep; 32(6):1066-1071. doi: 10.1002/bio.3292. [PMID: 28303653]
  • Yasaman Sefid-Sefidehkhan, Khadijeh Nekoueian, Mandana Amiri, Mika Sillanpaa, Habibollah Eskandari. Palladium nanoparticles in electrochemical sensing of trace terazosin in human serum and pharmaceutical preparations. Materials science & engineering. C, Materials for biological applications. 2017 Jun; 75(?):368-374. doi: 10.1016/j.msec.2017.02.061. [PMID: 28415474]
  • Hafiz Mohammad Rashid Nadeem, Ejaz Mohiuddin, Shahab UdDin, Muhammad Daniyal, Khan Usmanghani. Comparison of Anti BPH capsule (herbal) and Terazosin HCl in the treatment of benign prostate hyperplasia. Pakistan journal of pharmaceutical sciences. 2017 Jan; 30(1 Suppl):289-293. doi: ". [PMID: 28625956]
  • Jian-Ming Sun, Peng Liu, Wen-Jun Han. [Efficacy and safety of Tonglin Powder in the treatment of benign prostatic hyperplasia]. Zhonghua nan ke xue = National journal of andrology. 2016 Oct; 22(10):897-901. doi: . [PMID: 29278471]
  • Ai Ping Li, Huanjun Peng, Jing Dong Peng, Ming Qiong Zhou, Jing Zhang. Rayleigh light scattering detection of three α1-adrenoceptor antagonists coupled with high performance liquid chromatograph. Spectrochimica acta. Part A, Molecular and biomolecular spectroscopy. 2015 Aug; 147(?):178-84. doi: 10.1016/j.saa.2015.02.062. [PMID: 25840026]
  • D Mitropoulos, E Patris, G Deliconstantinos, A Kyroudi-Voulgari, I Anastasiou, D Perea. Terazosin-induced alterations in catalase expression and lipid peroxidation in the rat seminal vesicles. Andrologia. 2013 Apr; 45(2):128-34. doi: 10.1111/j.1439-0272.2012.01324.x. [PMID: 22731390]
  • Minoru Miyazato, Takuma Oshiro, Michael B Chancellor, William C de Groat, Naoki Yoshimura, Seiichi Saito. An alpha1-adrenoceptor blocker terazosin improves urine storage function in the spinal cord in spinal cord injured rats. Life sciences. 2013 Feb; 92(2):125-30. doi: 10.1016/j.lfs.2012.11.006. [PMID: 23178151]
  • Man Liu, Dan Zhang, Man Yang, Ting Zhao, Xiaolin Wang, Yanan Zhang, Jing Han, Huichen Liu. Pharmacokinetics of terazosin enantiomers in healthy Chinese male subjects. Chirality. 2012 Dec; 24(12):1047-50. doi: 10.1002/chir.22095. [PMID: 22887707]
  • Britta J Veitenheimer, William C Engeland, Pilar A Guzman, Gregory D Fink, John W Osborn. Effect of global and regional sympathetic blockade on arterial pressure during water deprivation in conscious rats. American journal of physiology. Heart and circulatory physiology. 2012 Oct; 303(8):H1022-34. doi: 10.1152/ajpheart.00413.2012. [PMID: 22904160]
  • Sanam Mustafa, Heng B See, Ruth M Seeber, Stephen P Armstrong, Carl W White, Sabatino Ventura, Mohammed Akli Ayoub, Kevin D G Pfleger. Identification and profiling of novel α1A-adrenoceptor-CXC chemokine receptor 2 heteromer. The Journal of biological chemistry. 2012 Apr; 287(16):12952-65. doi: 10.1074/jbc.m111.322834. [PMID: 22371491]
  • E E Filyushina, M D Shmerling, V A Lazarev, I I Buzueva, A L Merkel, G S Yakobson. Structural characteristics of renal glomerular system in ISIAH rats under conditions of chronic stress and preventive hypotensive drug therapy. Bulletin of experimental biology and medicine. 2011 Dec; 152(2):249-52. doi: 10.1007/s10517-011-1500-z. [PMID: 22808472]
  • Dean Sol Elterman, Nathan Lawrentschuk, Emma Guns, Karen Hersey, Hans Adomat, Catherine A Wood, Neil Fleshner. Investigating contamination of phytotherapy products for benign prostatic hyperplasia with alpha-blockers and 5alpha-reductase inhibitors. The Journal of urology. 2010 May; 183(5):2085-9. doi: 10.1016/j.juro.2009.12.097. [PMID: 20303529]
  • Shao Li, Aiping Lu, Yongyan Wang. Symptomatic comparison in efficacy on patients with benign prostatic hyperplasia treated with two therapeutic approaches. Complementary therapies in medicine. 2010 Feb; 18(1):21-7. doi: 10.1016/j.ctim.2009.10.002. [PMID: 20178875]
  • Mohan K Abraham, Abdul Rasheed A Nasir, Bindu Sudarsanan, Ramakrishnan Puzhankara, Prashant M Kedari, Gopidas R Unnithan, Kalyan Ravi Prasad Damisetti, Tutu Narayanan. Role of alpha adrenergic blocker in the management of posterior urethral valves. Pediatric surgery international. 2009 Dec; 25(12):1113-5. doi: 10.1007/s00383-009-2469-9. [PMID: 19727771]
  • Jerry G Blaivas. A round table discussion: case studies of patients with lower urinary tract symptoms. The Urologic clinics of North America. 2009 Nov; 36(4):537-69, vii. doi: 10.1016/j.ucl.2009.08.006. [PMID: 19942051]
  • Hong-Yan Zou, Hai-Long Wu, Li-Qun OuYang, Yan Zhang, Jin-Fang Nie, Hai-Yan Fu, Ru-Qin Yu. Fluorescent quantification of terazosin hydrochloride content in human plasma and tablets using second-order calibration based on both parallel factor analysis and alternating penalty trilinear decomposition. Analytica chimica acta. 2009 Sep; 650(1):143-9. doi: 10.1016/j.aca.2009.07.022. [PMID: 19720185]
  • O V Teodorovich, N B Zabrodina, A B Bochkarev. [Using setegis (terasosine) in early postoperative period after transurethral prostate resection]. Urologiia (Moscow, Russia : 1999). 2009 May; ?(3):62-4. doi: . [PMID: 19673124]
  • Chung-Jing Wang, Shi-Wei Huang, Chien-Hsing Chang. Adjunctive medical therapy with an alpha-1A-specific blocker after shock wave lithotripsy of lower ureteral stones. Urologia internationalis. 2009; 82(2):166-9. doi: 10.1159/000200793. [PMID: 19322003]
  • Kohji Takara, Toshiyuki Sakaeda, Mikio Kakumoto, Yusuke Tanigawara, Hironao Kobayashi, Katsuhiko Okumura, Noriaki Ohnishi, Teruyoshi Yokoyama. Effects of alpha-adrenoceptor antagonist doxazosin on MDR1-mediated multidrug resistance and transcellular transport. Oncology research. 2009; 17(11-12):527-33. doi: 10.3727/096504009789745601. [PMID: 19806783]
  • Tao Yang, Xing-Qiao Zhang, Yong-Wei Feng. [Efficacy of electroacupuncture in treating 93 patients with benign prostatic hyperplasia]. Zhongguo Zhong xi yi jie he za zhi Zhongguo Zhongxiyi jiehe zazhi = Chinese journal of integrated traditional and Western medicine. 2008 Nov; 28(11):998-1000. doi: ". [PMID: 19213342]
  • Rahmi Onur, Cemal Tasdemir, Dilara Seckin, Necip Ilhan, Selim Kutlu, Nusret Akpolat. Combined use of melatonin and terazosin restores bladder contractility in rabbits with partial outlet obstruction. Urology. 2008 Aug; 72(2):439-43. doi: 10.1016/j.urology.2008.02.053. [PMID: 18455780]
  • Jae-Seung Paick, Min Chul Cho, Sang Hoon Song, Soo Woong Kim, Ja Hyeon Ku. Impacts of the quinazoline-based alpha1-antagonist, terazosin, and of the sulfonamide derivative, tamsulosin, on serum prostate-specific antigen and prostate volume. Journal of Korean medical science. 2008 Jun; 23(3):509-13. doi: 10.3346/jkms.2008.23.3.509. [PMID: 18583890]
  • Bee Yean Low, Men Long Liong, Kah Hay Yuen, Christopher Chee, Wing Seng Leong, Wooi Loong Chong, Nurzalina Abdul Karim Khan, Phaik Yeong Cheah, Ker Keong Liong. Terazosin therapy for patients with female lower urinary tract symptoms: a randomized, double-blind, placebo controlled trial. The Journal of urology. 2008 Apr; 179(4):1461-9. doi: 10.1016/j.juro.2007.11.060. [PMID: 18295277]
  • L E Randle, J G Sathish, N R Kitteringham, I Macdonald, D P Williams, B K Park. alpha(1)-Adrenoceptor antagonists prevent paracetamol-induced hepatotoxicity in mice. British journal of pharmacology. 2008 Feb; 153(4):820-30. doi: 10.1038/sj.bjp.0707620. [PMID: 18071297]
  • Miguel Angel Campanero, Belén Sádaba, Maria José Muñoz-Juarez, Emilio García Quetglas, Jose Ramón Azanza. Pharmacokinetic and pharmacodynamic modelling of arterial haemodynamic effects of terazosin in healthy volunteers. Clinical drug investigation. 2008; 28(3):139-47. doi: 10.2165/00044011-200828030-00001. [PMID: 18266399]
  • Phillip P Smith, Eric Hurtado, Christopher P Smith, Timothy B Boone, George T Somogyi. Comparison of cystometric methods in female rats. Neurourology and urodynamics. 2008; 27(4):324-9. doi: 10.1002/nau.20512. [PMID: 17849479]
  • Zhi-Ling Zhou, Min Yang, Xi-Yong Yu, Huai-Yan Peng, Zhi-Xin Shan, Shu-Zhen Chen, Qiu-Xiong Lin, Xiao-Ying Liu, Tie-Feng Chen, Shu-Feng Zhou, Shu-Guang Lin. A rapid and simple high-performance liquid chromatography method for the determination of human plasma levofloxacin concentration and its application to bioequivalence studies. Biomedical chromatography : BMC. 2007 Oct; 21(10):1045-51. doi: 10.1002/bmc.851. [PMID: 17549677]
  • Ning-chen Li, Shi-liang Wu, Jie Jin, Shao-peng Qiu, Chui-ze Kong, Yong-sheng Song, Zhang-qun Ye, Guang Sun, Ying-hao Sun, Yu-cheng Sun, Xiao-feng Wang, Yan-qun Na. [Comparison of different drugs on the treatment of benign prostate hyperplasia]. Zhonghua wai ke za zhi [Chinese journal of surgery]. 2007 Jul; 45(14):947-50. doi: . [PMID: 17961376]
  • Shizuo Yamada, Yasuhiro Kato, Takashi Okura, Yoshiyuki Kagawa, Kazuki Kawabe. Prediction of alpha1-adrenoceptor occupancy in the human prostate from plasma concentrations of silodosin, tamsulosin and terazosin to treat urinary obstruction in benign prostatic hyperplasia. Biological & pharmaceutical bulletin. 2007 Jul; 30(7):1237-41. doi: 10.1248/bpb.30.1237. [PMID: 17603160]
  • E E Filyushina, M D Shmerling, V A Lazarev, I I Buzuyeva, A L Markel', G S Yakobson. Delayed effects of hypotensive drugs on structural characteristics of the renal glomerular system in hypertensive NISAG rats. Bulletin of experimental biology and medicine. 2007 Jun; 143(6):749-52. doi: 10.1007/s10517-007-0232-6. [PMID: 18239819]
  • E Y Oh, S K Bae, J W Kwon, M You, D C Lee, M G Lee. Pharmacokinetic and pharmacodynamic consequences of inhibition of terazosin metabolism via CYP3A1 and/or 3A2 by DA-8159, an erectogenic, in rats. British journal of pharmacology. 2007 May; 151(1):24-34. doi: 10.1038/sj.bjp.0707192. [PMID: 17351661]
  • Yong Yang, Xiao-feng Zhao, Han-zhong Li, Wei Wang, Yong Zhang, He Xiao, Xin Zhang. Efficacy and safety of combined therapy with terazosin and tolteradine for patients with lower urinary tract symptoms associated with benign prostatic hyperplasia: a prospective study. Chinese medical journal. 2007 Mar; 120(5):370-4. doi: . [PMID: 17376305]
  • Dionisios Mitropoulos, Eleni Papakonstantinou, Alexios J Aletras, Nikolaos Kalinderis, Anastasios Zervas, Dimitrios Hatzichristou, George Karakiulakis. Terazosin modifies the content of glycosaminoglycans and the activity of matrix metalloproteinase 2 in the rat ventral prostate. European urology. 2007 Feb; 51(2):447-56; discussion 456. doi: 10.1016/j.eururo.2006.06.028. [PMID: 16899336]
  • Rameshwar Jatwa, Anand Kar. Cardio-protective role of terazosin is possibly mediated through alteration in thyroid function. European journal of pharmacology. 2006 Dec; 551(1-3):87-91. doi: 10.1016/j.ejphar.2006.08.074. [PMID: 17027746]
  • Thomas M Kessler, Urs E Studer, Fiona C Burkhard. The effect of terazosin on functional bladder outlet obstruction in women: a pilot study. The Journal of urology. 2006 Oct; 176(4 Pt 1):1487-92. doi: 10.1016/j.juro.2006.06.009. [PMID: 16952666]
  • V G Gomberg, Iu T Nad'. [Using terasosine (setegis) in the treatment of hyperactive urinary bladder in elderly women]. Urologiia (Moscow, Russia : 1999). 2006 Sep; ?(5):63-7, 71. doi: NULL. [PMID: 17444155]
  • A K M Anwarul Islam, M A Kashem, I A Shameem, S A M G Kibria. Efficacy of terazosin and finasteride in symptomatic benign prostatic hyperplasia: A comparative study. Bangladesh Medical Research Council bulletin. 2005 Aug; 31(2):54-61. doi: . [PMID: 16967810]
  • NULL. [Kornam in the treatment of imperative urine incontinence in females]. Urologiia (Moscow, Russia : 1999). 2005 May; ?(3):26-8. doi: NULL. [PMID: 16097709]
  • M F Trapeznikova, M A Gurevich, K V Pozdniakov, S Ia Tazina, N V Bychkova. [Clinical efficacy and safety of terazosine (setegis) in patients with benign prostatic hyperplasia with concomitant cardiovascular diseases]. Urologiia (Moscow, Russia : 1999). 2005 Mar; ?(2):50-3. doi: . [PMID: 15989029]
  • A V Sivkov, V N Oshchepkov, A A Egorov. [Double-blind placebo-controlled trial of terazosine efficacy in patients with chronic abacterial prostatitis]. Urologiia (Moscow, Russia : 1999). 2005 Jan; ?(1):47-53. doi: . [PMID: 15776832]
  • Albaha Barqawi, Eduard Gamito, Colin O'Donnell, E David Crawford. Herbal and vitamin supplement use in a prostate cancer screening population. Urology. 2004 Feb; 63(2):288-92. doi: 10.1016/j.urology.2003.09.019. [PMID: 14972473]
  • Murat Bozlu, Ercüment Ulusoy, Selahittin Cayan, Esen Akbay, Sadik Görür, Erdem Akbay. A comparison of four different alpha1-blockers in benign prostatic hyperplasia patients with and without diabetes. Scandinavian journal of urology and nephrology. 2004; 38(5):391-5. doi: 10.1080/00365590410015678. [PMID: 15764250]
  • Wei-ru Zhang, Ming Sun, Jie-kun Luo. [Serum nitric oxide and D-dimer before and after administering antihypertensive drugs in essential hypertension]. Hunan yi ke da xue xue bao = Hunan yike daxue xuebao = Bulletin of Hunan Medical University. 2003 Aug; 28(4):382-4. doi: NULL. [PMID: 14653123]
  • Eric A Stone, Gary L Grunewald, Yan Lin, Rashedul Ahsan, Helen Rosengarten, H Kenneth Kramer, David Quartermain. Role of epinephrine stimulation of CNS alpha1-adrenoceptors in motor activity in mice. Synapse (New York, N.Y.). 2003 Jul; 49(1):67-76. doi: 10.1002/syn.10212. [PMID: 12710017]
  • P Kotridis, B Kokkas, P Kyriakou, M Karamouzis, G Salpigidis, C Karantona, J Karadoumanis, T Ginis, O Goulis, P C Papadopoulos, C Vakalopoulos, G Sakantamis, A Dimitriadou, V Mirtsou-Fidani, C L Papadopoulos. Plasma atrial natriuretic peptide in essential hypertension after treatment with terazocin. European journal of drug metabolism and pharmacokinetics. 2003 Apr; 28(2):143-6. doi: 10.1007/bf03190503. [PMID: 12877573]
  • Phaik Yeong Cheah, Men Long Liong, Kah Hay Yuen, Chu Leong Teh, Timothy Khor, Jin Rong Yang, Hin Wai Yap, John N Krieger. Terazosin therapy for chronic prostatitis/chronic pelvic pain syndrome: a randomized, placebo controlled trial. The Journal of urology. 2003 Feb; 169(2):592-6. doi: 10.1097/01.ju.0000042927.45683.6c. [PMID: 12544314]
  • E I Veliev, S B Petrov. [Results of treatment of irritative symptoms and urinary retention in patients 1 year after radical retropubic prostatectomy]. Urologiia (Moscow, Russia : 1999). 2003 Jan; ?(1):15-7. doi: NULL. [PMID: 12621960]
  • A Bur, C Woisetschläger, H Herkner, U Derhaschnig, P Quehenberger, M M Hirschl. [Effects of terazosine and atenolol on serum lipids in essential hypertension]. Zeitschrift fur Kardiologie. 2002 Sep; 91(9):685-92. doi: 10.1007/s00392-002-0814-2. [PMID: 12448067]
  • Sharyn M Fitzgerald, Michael W Brands. Hypertension in L-NAME-treated diabetic rats depends on an intact sympathetic nervous system. American journal of physiology. Regulatory, integrative and comparative physiology. 2002 Apr; 282(4):R1070-6. doi: 10.1152/ajpregu.00468.2001. [PMID: 11893611]
  • Jean J M C H de la Rosette, Barbara B M Kortmann, Cristina Rossi, Gabe S Sonke, Diamandis L Floratos, Lambertus A L M Kiemeney. Long-term risk of re-treatment of patients using alpha-blockers for lower urinary tract symptoms. The Journal of urology. 2002 Apr; 167(4):1734-9. doi: 10.1097/00005392-200204000-00035. [PMID: 11912399]
  • Bao Jun Gu, Osamu Ishizuka, Yasuhiko Igawa, Osamu Nishizawa, Karl-Erik Andersson. Role of supraspinal alpha1-adrenoceptors for voiding in conscious rats with and without bladder outlet obstruction. The Journal of urology. 2002 Apr; 167(4):1887-91. doi: NULL. [PMID: 11912454]
  • T J Wilt, R W Howe, I R Rutks, R MacDonald. Terazosin for benign prostatic hyperplasia. The Cochrane database of systematic reviews. 2002; ?(4):CD003851. doi: 10.1002/14651858.cd003851. [PMID: 12519611]
  • B Akduman, E D Crawford. Terazosin, doxazosin, and prazosin: current clinical experience. Urology. 2001 Dec; 58(6 Suppl 1):49-54. doi: 10.1016/s0090-4295(01)01302-4. [PMID: 11750252]
  • S A Kaplan. 5alpha-reductase inhibitors: what role should they play?. Urology. 2001 Dec; 58(6 Suppl 1):65-70; discussion 70. doi: 10.1016/s0090-4295(01)01347-4. [PMID: 11750255]
  • K Isen, Z Sinik, T Alkibay, C Sezer, S Sözen, S Atilla, O Ataoglu , S Isik. Magnetic resonance imaging and morphometric histologic analysis of prostate tissue composition in predicting the clinical outcome of terazosin therapy in benign prostatic hyperplasia. International journal of urology : official journal of the Japanese Urological Association. 2001 Feb; 8(2):42-8. doi: 10.1046/j.1442-2042.2001.00243.x. [PMID: 11240824]
  • E Akbay, M Bozlu, E Doruk, E Akbay, S Cayan, E Ulusoy. Effect of terazosin on the lipid profile in patients with symptomatic benign prostatic hyperplasia. Urologia internationalis. 2001; 67(2):156-9. doi: 10.1159/000050973. [PMID: 11490211]
  • B C Kang, C Q Yang, J E Rhee, O K Suh, W G Shin. High-performance liquid chromatographic analysis and pharmacokinetics of terazosin in healthy volunteers. Research communications in molecular pathology and pharmacology. 2001; 110(5-6):371-7. doi: NULL. [PMID: 12889528]
  • S Dutkiewics. Efficacy and tolerability of drugs for treatment of benign prostatic hyperplasia. International urology and nephrology. 2001; 32(3):423-32. doi: 10.1023/a:1017595818158. [PMID: 11583366]
  • T Gomi, T Ikeda, Y Shibuya, R Nagao. Effects of antihypertensive treatment on platelet function in essential hypertension. Hypertension research : official journal of the Japanese Society of Hypertension. 2000 Nov; 23(6):567-72. doi: 10.1291/hypres.23.567. [PMID: 11131267]
  • H A Mosli, M A Atwa, S H Mahassini. Benign prostatic hyperplasia. The Saudi perspective in the year 2000. Saudi medical journal. 2000 Oct; 21(10):915-20. doi: NULL. [PMID: 11369951]
  • P Y Cheah, K H Yuen, M L Liong. Improved high-performance liquid chromatographic analysis of terazosin in human plasma. Journal of chromatography. B, Biomedical sciences and applications. 2000 Aug; 745(2):439-43. doi: 10.1016/s0378-4347(00)00313-3. [PMID: 11043762]
  • L Caprino. [Drugs for the treatment of benign prostatic hypertrophy]. Minerva urologica e nefrologica = The Italian journal of urology and nephrology. 2000 Jun; 52(2):87-92. doi: . [PMID: 11085067]
  • T Tsujii. Comparison of prazosin, terazosin and tamsulosin in the treatment of symptomatic benign prostatic hyperplasia: a short-term open, randomized multicenter study. BPH Medical Therapy Study Group. Benign prostatic hyperplasia. International journal of urology : official journal of the Japanese Urological Association. 2000 Jun; 7(6):199-205. doi: 10.1046/j.1442-2042.2000.00175.x. [PMID: 10843450]
  • V Antic, F Kiener-Belforti, A Tempini, B N Van Vliet, J P Montani. Role of the sympathetic nervous system during the development of obesity-induced hypertension in rabbits. American journal of hypertension. 2000 May; 13(5 Pt 1):556-9. doi: 10.1016/s0895-7061(99)00267-8. [PMID: 10826410]
  • H Okada, S Kamidono, T Yoshioka, A Okuyama, S Ozono, Y Hirao, E Okajima, K Yamamoto, T Kishimoto, Y Park, T Kurita. A comparative study of terazosin and tamsulosin for symptomatic benign prostatic hyperplasia in Japanese patients. BJU international. 2000 Apr; 85(6):676-81. doi: 10.1046/j.1464-410x.2000.00608.x. [PMID: 10759664]
  • R M Zusman. The role of alpha 1-blockers in combination therapy for hypertension. International journal of clinical practice. 2000 Jan; 54(1):36-40. doi: NULL. [PMID: 10750258]
  • J K Bennett, J Foote, T R El-Leithy, M D Saleem, B Green, C L Archer, M Gray. Terazosin for vesicosphincter dyssynergia in spinal cord-injured male patients. Molecular urology. 2000; 4(4):415-20. doi: NULL. [PMID: 11156710]
  • M Tamaki, T Ueda, S Kageyama. [Evaluation of serum lipid levels in clinical benign prostatic hyperplasia patients with terazosin monotherapy]. Hinyokika kiyo. Acta urologica Japonica. 1999 Dec; 45(12):827-30. doi: NULL. [PMID: 10659415]
  • M K Brawer, D W Lin, W O Williford, K Jones, H Lepor. Effect of finasteride and/or terazosin on serum PSA: results of VA Cooperative Study #359. The Prostate. 1999 Jun; 39(4):234-9. doi: 10.1002/(sici)1097-0045(19990601)39:4<234::aid-pros3>3.0.co;2-4. [PMID: 10344212]
  • P C Albertsen, J M Pellissier, F C Lowe, C J Girman, C G Roehrborn. Economic analysis of finasteride: a model-based approach using data from the Proscar Long-Term Efficacy and Safety Study. Clinical therapeutics. 1999 Jun; 21(6):1006-24. doi: 10.1016/s0149-2918(99)80021-6. [PMID: 10440624]
  • F Pasanisi, G Imperatore, O Vaccaro, C Iovine, L A Ferrara. Effects of a 3-month treatment with terazosin on fasting and postprandial glucose and lipid metabolism in type 2 diabetic patients with hypertension. Nutrition, metabolism, and cardiovascular diseases : NMCD. 1999 Apr; 9(2):73-7. doi: . [PMID: 10726112]
  • P Gong, J Tang, L Cheng, Z Lu, J Zhang, F Zeng. Effect of terazosin on blood pressure and serum lipids. Journal of Tongji Medical University = Tong ji yi ke da xue xue bao. 1999; 19(4):291-4. doi: 10.1007/bf02886966. [PMID: 12938521]
  • V Vashi, M Chung, J Hilbert, V Lawrence, K Phillips. Pharmacokinetic interaction between finasteride and terazosin, but not finasteride and doxazosin. Journal of clinical pharmacology. 1998 Nov; 38(11):1072-6. doi: 10.1177/009127009803801113. [PMID: 9824790]
  • J K Bubien, T Cornwell, A L Bradford, C M Fuller, M D DuVall, D J Benos. Alpha-adrenergic receptors regulate human lymphocyte amiloride-sensitive sodium channels. The American journal of physiology. 1998 09; 275(3):C702-10. doi: 10.1152/ajpcell.1998.275.3.c702. [PMID: 9730954]
  • E C Sekhar, T R Rao, K R Sekhar, M U Naidu, J C Shobha, P U Rani, T V Kumar, V P Kumar. Determination of terazosin in human plasma, using high-performance liquid chromatography with fluorescence detection. Journal of chromatography. B, Biomedical sciences and applications. 1998 Jun; 710(1-2):137-42. doi: 10.1016/s0378-4347(98)00120-0. [PMID: 9686880]
  • S S O'Malley, T B Chen, B E Francis, R E Gibson, H D Burns, J DiSalvo, M L Bayne, J M Wetzel, D Nagarathnam, M Marzabadi, C Gluchowski, R S Chang. Characterization of specific binding of [125I]L-762,459, a selective alpha1A-adrenoceptor radioligand to rat and human tissues. European journal of pharmacology. 1998 May; 348(2-3):287-95. doi: 10.1016/s0014-2999(98)00149-6. [PMID: 9652345]
  • C R Chapple. Pharmacotherapy for benign prostatic hyperplasia--the potential for alpha 1-adrenoceptor subtype-specific blockade. British journal of urology. 1998 Mar; 81 Suppl 1(?):34-47; discussion 64. doi: 10.1046/j.1464-410x.1998.0810s1034.x. [PMID: 9589016]
  • A P Zavitsanos, T Alebic-Kolbah. Enantioselective determination of terazosin in human plasma by normal phase high-performance liquid chromatography-electrospray mass spectrometry. Journal of chromatography. A. 1998 Jan; 794(1-2):45-56. doi: 10.1016/s0021-9673(97)00892-3. [PMID: 9491556]
  • K Taguchi, R F Schäfers, M C Michel. Radioreceptor assay analysis of tamsulosin and terazosin pharmacokinetics. British journal of clinical pharmacology. 1998 Jan; 45(1):49-55. doi: 10.1046/j.1365-2125.1998.00636.x. [PMID: 9489594]
  • T Ohkura, S Yamada, Y Deguchi, R Kimura, H Matsushima, S Higuchi, O Inagaki, K Honda, T Takenaka. Ex vivo occupancy by tamsulosin of alpha1-adrenoceptors in rat tissues in relation to the plasma concentration. Life sciences. 1998; 63(24):2147-55. doi: 10.1016/s0024-3205(98)00495-0. [PMID: 9851306]
  • D W Keetch, G L Andriole, T L Ratliff, W J Catalona. Comparison of percent free prostate-specific antigen levels in men with benign prostatic hyperplasia treated with finasteride, terazosin, or watchful waiting. Urology. 1997 Dec; 50(6):901-5. doi: 10.1016/s0090-4295(97)00453-6. [PMID: 9426721]
  • C G Roehrborn, J E Oesterling, P J Olson, R J Padley. Serial prostate-specific antigen measurements in men with clinically benign prostatic hyperplasia during a 12-month placebo-controlled study with terazosin. HYCAT Investigator Group. Hytrin Community Assessment Trial. Urology. 1997 Oct; 50(4):556-61. doi: 10.1016/s0090-4295(97)00302-6. [PMID: 9338731]
  • E Lee, C Lee. Clinical comparison of selective and non-selective alpha 1A-adrenoreceptor antagonists in benign prostatic hyperplasia: studies on tamsulosin in a fixed dose and terazosin in increasing doses. British journal of urology. 1997 Oct; 80(4):606-11. doi: 10.1046/j.1464-410x.1997.00411.x. [PMID: 9352700]
  • D G Witte, M E Brune, S P Katwala, I Milicic, J F Kerwin, A A Hancock. Relationships between pharmacokinetics and blockade of agonist-induced prostatic intraurethral pressure and mean arterial pressure in the conscious dog after single and repeated daily oral administration of terazosin. The Journal of pharmacology and experimental therapeutics. 1997 Aug; 282(2):891-8. doi: NULL. [PMID: 9262356]
  • K S Cabell, L Ma, P Johnson. Effects of antihypertensive drugs on rat tissue antioxidant enzyme activities and lipid peroxidation levels. Biochemical pharmacology. 1997 Jul; 54(1):133-41. doi: 10.1016/s0006-2952(97)00161-5. [PMID: 9296359]
  • T Becopoulos, D Mitropoulos, I Christofis. Influence of prostate size on terazosin efficacy. International journal of urology : official journal of the Japanese Urological Association. 1997 Jul; 4(4):358-61. doi: 10.1111/j.1442-2042.1997.tb00208.x. [PMID: 9256324]